Cargando…

Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020

BACKGROUND: The SARS-CoV-2 pandemic spread across Europe from February 2020. While robust SARS-CoV-2 serological assays were quickly developed, only limited information on applied serological testing is available. We describe the extent and nature of SARS-CoV-2 serological testing used in Europe and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bubba, Laura, Simmonds, Peter, Fischer, Thea K, Harvala, Heli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Global Health 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364255/
https://www.ncbi.nlm.nih.gov/pubmed/34408857
http://dx.doi.org/10.7189/jogh.11.05014
_version_ 1783738495120965632
author Bubba, Laura
Simmonds, Peter
Fischer, Thea K
Harvala, Heli
author_facet Bubba, Laura
Simmonds, Peter
Fischer, Thea K
Harvala, Heli
author_sort Bubba, Laura
collection PubMed
description BACKGROUND: The SARS-CoV-2 pandemic spread across Europe from February 2020. While robust SARS-CoV-2 serological assays were quickly developed, only limited information on applied serological testing is available. We describe the extent and nature of SARS-CoV-2 serological testing used in Europe and assess the links between epidemiology, mitigation strategies applied and seroprevalence. METHODS: An online questionnaire on SARS-CoV-2 serology was sent to the European Society of Clinical Virology and European Non-Polio Enterovirus Network members in September 2020. Data were analysed by comparing mitigation approaches, serological methods and seroprevalance studies performed. RESULTS: About 100 000 laboratory confirmed cases identified between March and June 2020 were reported by 36 participating laboratories from 20 countries. All responders experienced mitigation strategies including lockdowns and other closures. All except one participant had introduced serological testing; most had validated their assays (n = 29), but some had had difficulties in obtaining reference material. Most used commercial assays (n = 35), measuring IgG response against the spike antigen. Serology was used primarily for diagnostic purposes (n = 22) but also for convalescent plasma (n = 13) and research studies (n = 30). Seroprevalence studies targeted mainly health care workers (n = 20; seroprevalance 5% to 22%) and general population (n = 16; seroprevalance 0.88% to 5.6%). Basic demographic and clinical information were collected by most laboratories (n = 28), whereas data on long-term outcomes were rarely collected. CONCLUSIONS: This is first study gathering systematic information on serological testing approaches implemented during the first pandemic wave in Europe.
format Online
Article
Text
id pubmed-8364255
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Society of Global Health
record_format MEDLINE/PubMed
spelling pubmed-83642552021-08-17 Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020 Bubba, Laura Simmonds, Peter Fischer, Thea K Harvala, Heli J Glob Health Research Theme 1: COVID-19 Pandemic BACKGROUND: The SARS-CoV-2 pandemic spread across Europe from February 2020. While robust SARS-CoV-2 serological assays were quickly developed, only limited information on applied serological testing is available. We describe the extent and nature of SARS-CoV-2 serological testing used in Europe and assess the links between epidemiology, mitigation strategies applied and seroprevalence. METHODS: An online questionnaire on SARS-CoV-2 serology was sent to the European Society of Clinical Virology and European Non-Polio Enterovirus Network members in September 2020. Data were analysed by comparing mitigation approaches, serological methods and seroprevalance studies performed. RESULTS: About 100 000 laboratory confirmed cases identified between March and June 2020 were reported by 36 participating laboratories from 20 countries. All responders experienced mitigation strategies including lockdowns and other closures. All except one participant had introduced serological testing; most had validated their assays (n = 29), but some had had difficulties in obtaining reference material. Most used commercial assays (n = 35), measuring IgG response against the spike antigen. Serology was used primarily for diagnostic purposes (n = 22) but also for convalescent plasma (n = 13) and research studies (n = 30). Seroprevalence studies targeted mainly health care workers (n = 20; seroprevalance 5% to 22%) and general population (n = 16; seroprevalance 0.88% to 5.6%). Basic demographic and clinical information were collected by most laboratories (n = 28), whereas data on long-term outcomes were rarely collected. CONCLUSIONS: This is first study gathering systematic information on serological testing approaches implemented during the first pandemic wave in Europe. International Society of Global Health 2021-07-31 /pmc/articles/PMC8364255/ /pubmed/34408857 http://dx.doi.org/10.7189/jogh.11.05014 Text en Copyright © 2021 by the Journal of Global Health. All rights reserved. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Research Theme 1: COVID-19 Pandemic
Bubba, Laura
Simmonds, Peter
Fischer, Thea K
Harvala, Heli
Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020
title Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020
title_full Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020
title_fullStr Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020
title_full_unstemmed Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020
title_short Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020
title_sort mapping of serological testing and sars-cov-2 seroprevalence studies performed in 20 european countries, march-june 2020
topic Research Theme 1: COVID-19 Pandemic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364255/
https://www.ncbi.nlm.nih.gov/pubmed/34408857
http://dx.doi.org/10.7189/jogh.11.05014
work_keys_str_mv AT bubbalaura mappingofserologicaltestingandsarscov2seroprevalencestudiesperformedin20europeancountriesmarchjune2020
AT simmondspeter mappingofserologicaltestingandsarscov2seroprevalencestudiesperformedin20europeancountriesmarchjune2020
AT fischertheak mappingofserologicaltestingandsarscov2seroprevalencestudiesperformedin20europeancountriesmarchjune2020
AT harvalaheli mappingofserologicaltestingandsarscov2seroprevalencestudiesperformedin20europeancountriesmarchjune2020